Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 2, 2011, Pages 375-380

  Shorr, Andrew F ^a   Wu, Chunzhang ^b   Kothari, Smita ^c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b Astellas Pharma US Inc   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

C. glabrata; C. krusei; Mortality

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; MICAFUNGIN;

ADULT; ARTICLE; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; HOSPITAL ADMISSION; HUMAN; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; HUMANS; LIPOPEPTIDES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 78651466517     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq446     Document Type: Article

References (16)

1. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
3. Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-8.
4. Méan M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008; 12: 204.
5. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
6. Labelle AJ, Micek ST, Roubinian N, et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36: 2967-72.
7. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
8. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
9. Cornely OA, De Waele J, Betts R, et al. An analysis of the efficacy of micafungin in Candida infections caused by non-albicans Candida species in phase III trials. In: Abstracts of the Seventeenth European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, 2007. Abstract p973, p. 257. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
10. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
11. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
12. Marriott DJ, Playford EG, Chen S, et al. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 2009; 13: R115.
13. Klevay MJ, Ernst EJ, Hollanbaugh JL, et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2008; 60: 273-7.
14. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother 2007; 41: 568-73.
15. Rodriguez D, Park BJ, Almirante B, et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007; 13: 788-93.
16. Raad I, Hanna H, Boktour M, et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004; 38: 1119-27.